MX2019000159A - Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa. - Google Patents
Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa.Info
- Publication number
- MX2019000159A MX2019000159A MX2019000159A MX2019000159A MX2019000159A MX 2019000159 A MX2019000159 A MX 2019000159A MX 2019000159 A MX2019000159 A MX 2019000159A MX 2019000159 A MX2019000159 A MX 2019000159A MX 2019000159 A MX2019000159 A MX 2019000159A
- Authority
- MX
- Mexico
- Prior art keywords
- pirida
- piridazin
- pirazolo
- pirrolo
- onas
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporcionan ciertos compuestos o sales farmacéuticamente aceptables de los mismos que pueden inhibir la actividad quinasa de la tirosina quinasa de Bruton (BTK) y pueden ser útiles para el tratamiento de enfermedades como el cáncer, las enfermedades inmunológicas y la inflamación.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662353535P | 2016-06-22 | 2016-06-22 | |
| US201662412768P | 2016-10-25 | 2016-10-25 | |
| PCT/CN2017/089123 WO2017219955A1 (en) | 2016-06-22 | 2017-06-20 | Substituted pyrrolo [2, 3-d] pyridazin-4-ones and pyrazolo [3, 4-d] pyridazin-4-ones as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019000159A true MX2019000159A (es) | 2019-05-30 |
| MX383514B MX383514B (es) | 2025-03-14 |
Family
ID=60783194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000159A MX383514B (es) | 2016-06-22 | 2017-06-20 | Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]piridazin-4-onas como inhibidores de la proteína quinasa. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10800785B2 (es) |
| EP (1) | EP3475286B1 (es) |
| JP (1) | JP6966044B2 (es) |
| KR (1) | KR102489537B1 (es) |
| CN (1) | CN109476666B (es) |
| AU (1) | AU2017280412B2 (es) |
| CA (1) | CA3028824C (es) |
| ES (1) | ES3030634T3 (es) |
| MX (1) | MX383514B (es) |
| RU (1) | RU2749038C2 (es) |
| TW (1) | TWI791444B (es) |
| WO (1) | WO2017219955A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022042612A1 (zh) * | 2020-08-27 | 2022-03-03 | 上海和誉生物医药科技有限公司 | 二氢吡咯并[2,3-d]哒嗪-7-酮衍生物，其制备方法和应用 |
| WO2022228387A1 (en) * | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| WO2014113942A1 (en) * | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| WO2014113932A1 (en) * | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| TW201441234A (zh) * | 2013-01-23 | 2014-11-01 | Merck Sharp & Dohme | Ｂｔｋ抑制劑 |
| EP3082809B1 (en) * | 2013-12-20 | 2021-01-20 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| CA2953798C (en) | 2014-07-07 | 2019-06-11 | Eternity Bioscience Inc. | Aminopyridazinone compounds as protein kinase inhibitors |
| CN105837576B (zh) * | 2015-01-14 | 2019-03-26 | 湖北生物医药产业技术研究院有限公司 | Btk抑制剂 |
-
2017
- 2017-06-20 JP JP2018566580A patent/JP6966044B2/ja active Active
- 2017-06-20 AU AU2017280412A patent/AU2017280412B2/en active Active
- 2017-06-20 WO PCT/CN2017/089123 patent/WO2017219955A1/en not_active Ceased
- 2017-06-20 ES ES17814693T patent/ES3030634T3/es active Active
- 2017-06-20 US US16/312,063 patent/US10800785B2/en active Active
- 2017-06-20 MX MX2019000159A patent/MX383514B/es unknown
- 2017-06-20 RU RU2019101016A patent/RU2749038C2/ru active
- 2017-06-20 KR KR1020197000846A patent/KR102489537B1/ko active Active
- 2017-06-20 CA CA3028824A patent/CA3028824C/en active Active
- 2017-06-20 CN CN201780038676.1A patent/CN109476666B/zh active Active
- 2017-06-20 EP EP17814693.2A patent/EP3475286B1/en active Active
- 2017-06-22 TW TW106120885A patent/TWI791444B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190026754A (ko) | 2019-03-13 |
| US20190161489A1 (en) | 2019-05-30 |
| TW201811792A (zh) | 2018-04-01 |
| CN109476666A (zh) | 2019-03-15 |
| TWI791444B (zh) | 2023-02-11 |
| AU2017280412B2 (en) | 2021-02-25 |
| BR112018076622A2 (pt) | 2019-04-02 |
| RU2019101016A (ru) | 2020-07-22 |
| JP6966044B2 (ja) | 2021-11-10 |
| RU2749038C2 (ru) | 2021-06-03 |
| CN109476666B (zh) | 2021-10-15 |
| EP3475286A1 (en) | 2019-05-01 |
| EP3475286A4 (en) | 2019-11-06 |
| US10800785B2 (en) | 2020-10-13 |
| EP3475286C0 (en) | 2025-03-26 |
| JP2019522651A (ja) | 2019-08-15 |
| WO2017219955A1 (en) | 2017-12-28 |
| KR102489537B1 (ko) | 2023-01-17 |
| EP3475286B1 (en) | 2025-03-26 |
| CA3028824A1 (en) | 2017-12-28 |
| MX383514B (es) | 2025-03-14 |
| AU2017280412A1 (en) | 2019-01-17 |
| ES3030634T3 (en) | 2025-07-01 |
| RU2019101016A3 (es) | 2020-07-22 |
| CA3028824C (en) | 2023-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001674A1 (es) | Inhibidores de imidazopirazina de tirosina quinasa de bruton. | |
| CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| GEAP202516803A (en) | Bicyclic amines as cdk2 inhibitors | |
| MX372673B (es) | Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| MX2016014248A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
| MX381890B (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos | |
| MX2016010519A (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| MX2017013797A (es) | Inhibidor de janus quinasa. | |
| MX2017016655A (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
| MX373318B (es) | 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer. | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| MX386547B (es) | Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer. | |
| CL2019001330A1 (es) | Inhibidores de la tirosina quinasa de bruton. | |
| CO2017004517A2 (es) | Inhibidores de las tirosina cinasas de bruton derivados de la 2, 3, 4, 9-tetrahidro-ih-carbazol-8- carboxamida y 9h-carbazol-l-carboxamida, composiciones que los comprenden y metodos de elaboration | |
| MX2016016583A (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| MX2017001177A (es) | Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin- 6-ylmetil) imidazo[1,2,b] [1,2,4]triazin-2-il]benzamida. | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| MX387969B (es) | Composiciones y compuestos terapéuticos, y métodos para su uso. | |
| MX395032B (es) | Ciertos inhibidores de la proteína quinasa. | |
| UY35344A (es) | Oestra-1,3,5(10),16-tetraeno-3-carboxamidas | |
| MX2020012826A (es) | Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k). | |
| MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. |